Last reviewed · How we verify
Live attenuated tetravalent dengue vaccine
Live attenuated tetravalent dengue vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | Live attenuated tetravalent dengue vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge (PHASE1)
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases (PHASE4)
- A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan (PHASE2, PHASE3)
- A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India (PHASE3)
- A Study in Children and Adolescents on the Effectiveness of Takeda's Licensed Dengue Vaccine TDV Against Hospitalization Due to Dengue Disease
- A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers (PHASE3)
- Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose (PHASE3)
- ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live attenuated tetravalent dengue vaccine CI brief — competitive landscape report
- Live attenuated tetravalent dengue vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Live attenuated tetravalent dengue vaccine
What is Live attenuated tetravalent dengue vaccine?
Live attenuated tetravalent dengue vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes Live attenuated tetravalent dengue vaccine?
Live attenuated tetravalent dengue vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Live attenuated tetravalent dengue vaccine in?
Live attenuated tetravalent dengue vaccine is in Phase 2.